Larimar Therapeutics, Inc.
Company Stats
- Market Cap
- $331.9M
- as of Sep 30, 2026
- Shares Outstanding
- 103.9M
- Free Float
- 84.6%
Income Statement
- Operating Income
- -$172.5M
- Net Income
- -$165.7M
- EBITDA
- -$172.1M
Cash Flow
- Free Cash Flow
- -$113.3M
- FCF Yield
- -34.1%
- Owner FCF Yield
- -36.2%
Balance Sheet
- Cash & Equivalents
- $85.4M
Returns & Capital
- SBC, 3Y Avg
- $7.8M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | — | -$113.3M | — |
| FY2024 | — | -$71.3M | — |
| FY2023 | — | -$33.6M | — |
| FY2022 | — | -$27.7M | — |
| FY2021 | — | -$42.4M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of October 11, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Healthcare Earnings: Demand Surges, Costs Bite Back